Hemophagocytic Lymphohistiocytosis (Familial)
A life-threatening genetic disorder of immune regulation causing uncontrolled inflammation, most often presenting in infancy and requiring urgent specialist treatment including hematopoietic stem cell transplant.
- Urgent Specialist Coordination
- HLH-Directed Therapy Access
- Transplant Center Connection
- Typical Onset
- Infancy / Early Childhood
- Key Genes
- PRF1, UNC13D, STX11, STXBP2
- Inheritance
- Autosomal Recessive
- Definitive Treatment
- Hematopoietic Stem Cell Transplant
Condition Overview
Familial Hemophagocytic Lymphohistiocytosis (HLH) is a rare, life-threatening genetic disorder of immune regulation in which cytotoxic T-cells and natural killer (NK) cells fail to properly eliminate activated immune cells, leading to a runaway inflammatory cascade often described as a cytokine storm.
Familial HLH is caused by inherited variants in genes โ most commonly PRF1, UNC13D, STX11, and STXBP2 โ that are essential for the cytotoxic granule pathway used by immune cells to kill infected or activated cells. Without this regulatory brake, the immune system becomes persistently and dangerously activated.
The condition most often presents in infancy or early childhood, frequently triggered by a viral infection, and progresses rapidly without treatment. Because untreated familial HLH is fatal in the great majority of cases, rapid recognition and urgent initiation of HLH-directed therapy, followed by hematopoietic stem cell transplantation, are central to survival.
Types and Variants
Familial HLH is classified by the specific underlying gene defect, which can influence age of onset and, in some cases, treatment approach.
Symptoms and Signs
Familial HLH typically presents acutely with a combination of persistent fever and systemic inflammatory features that rapidly progress without treatment.
Causes and Risk Factors
Familial HLH is caused by inherited loss-of-function variants in genes essential to the cytotoxic granule pathway, almost always inherited in an autosomal recessive pattern.
Diagnosis and Investigations
Diagnosis combines fulfillment of validated HLH clinical and laboratory criteria with genetic confirmation of a familial HLH gene variant, pursued urgently given the time-sensitive nature of the disease.
Disease Severity and Urgency Classification
Familial HLH does not use formal staging; instead, clinicians classify severity by organ involvement and response to initial therapy, which determines transplant urgency.
Standard Treatment Options
Treatment proceeds in two urgent phases: rapidly suppressing the life-threatening hyperinflammatory state, then pursuing hematopoietic stem cell transplantation, which is the only treatment that addresses the underlying genetic defect.
Advanced and Emerging Treatment Options
Beyond standard induction chemotherapy, targeted immunologic approaches are increasingly used to control hyperinflammation while bridging to transplant.
Targeted Biologic
Emapalumab (anti-interferon-gamma monoclonal antibody)
Approved for primary HLH refractory to or intolerant of conventional therapy, directly neutralizing a key driver cytokine.
Cellular Therapy
Allogeneic hematopoietic stem cell transplant
The definitive, potentially curative treatment for familial HLH, replacing the genetically defective immune system.
Targeted Biologic
IL-1 or IL-6 pathway blockade (selected cases)
Used in some patients to control associated hyperinflammation, particularly with macrophage activation syndrome overlap.
Gene Therapy
Gene therapy approaches for select monogenic forms
Under early investigation as a potential alternative to allogeneic transplant for specific genetic subtypes.
Biomarkers and Precision Medicine
Laboratory and genetic markers are central to both diagnosing familial HLH urgently and monitoring response to treatment.
When a Second Opinion May Be Important
Because familial HLH is rare, rapidly progressive, and managed at specialized centers, several situations warrant urgent specialist re-evaluation.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Familial HLH is a life-threatening condition that is fatal in the great majority of cases without treatment; however, with rapid diagnosis, urgent HLH-directed therapy, and timely hematopoietic stem cell transplantation, meaningful long-term survival is achievable for many patients.
Supportive Care and Living With Familial HLH
Supporting a child or family through familial HLH involves intensive medical coordination alongside emotional and practical support during a high-acuity illness course.
How CancerFax Helps You Explore Treatment Options
CancerFax can help urgently coordinate review of HLH diagnostic and genetic test results, facilitate rapid second opinions, and connect families with specialized hematology and stem cell transplant centers experienced in familial HLH.
Get a free case reviewFrequently Asked Questions
Familial HLH is a rare, life-threatening genetic disorder in which the immune system loses its ability to regulate itself, leading to overwhelming inflammation that can rapidly damage multiple organs without urgent treatment.
Persistent high fever, an enlarged liver or spleen, and abnormal blood counts (low platelets, low red cells) are typical early signs, often following a triggering infection.
Yes โ it is caused by inherited variants in genes such as PRF1, UNC13D, STX11, or STXBP2, typically in an autosomal recessive pattern, meaning both parents carry one variant copy each.
Diagnosis combines standardized clinical and laboratory criteria (fever, cytopenias, elevated ferritin, and related findings) with functional immune testing and genetic confirmation, pursued urgently given the severity of the disease.
Without prompt treatment, the uncontrolled inflammatory cascade can rapidly cause multi-organ failure and death, making same-day specialist evaluation critical when it is suspected.
Treatment starts with urgent HLH-directed therapy to control the hyperinflammatory state, followed by hematopoietic stem cell transplantation, which is the only treatment that addresses the underlying genetic immune defect.
Yes โ because familial HLH is caused by a permanent genetic defect, relapse is expected without transplant, so it is considered for essentially all genetically confirmed cases.
Yes โ because of the recessive inheritance pattern, siblings can carry the same genetic variants, making early genetic counseling and testing important for the family.
Hematopoietic stem cell transplant can be curative for many patients with familial HLH by replacing the defective immune system, although outcomes depend on how quickly treatment is started and how the body responds.
Yes. Given how time-sensitive this condition is, CancerFax can help urgently coordinate review of diagnostic and genetic reports, facilitate rapid second opinions, and connect families with specialized hematology and stem cell transplant centers experienced in familial HLH.
Get Urgent Specialist Support for Familial HLH
Send diagnostic and genetic reports for urgent specialist review and explore stem cell transplant center options.